-
1h 1m 19sPart 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations
-
53m 32sPart 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2)
-
1h 2m 37sPart 1 | Session 11 Plenary Session 5: Managing side effects of HF drugs
-
37m 5sPart 1 | Session 12 Meet the expert: Sex differences in advanced heart failure
-
1h 1m 4sPart 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF
-
1h 2m 46sPart 2 | Session 1 Plenary Session 7: New technologies to manage your patients
-
1h 4m 11sPart 2 | Session 3 Plenary Session 8: New technologies to treat your patients
-
1h 9sPart 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines
-
1h 1m 38s
-
1h 1m 4sPart 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
-
1h 1m 28sPart 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
-
1h 1m 14s
-
1h 22sPart 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1)
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Faculty Biographies
Maurizio Volterrani
Head of the Cardiological Rehabilitation Unit
Full Professor in of Exercise Science and Medicine at San Raffaele Telematic University of Rome. Head of the Cardiac Pulmonary Department at IRCCS San Raffaele in Rome. Prof Volterrani’s main research interests include heart failure, exercise training in cardiac rehabilitation, telemedicine, hyperkalaemia and kidney failure . He is and has been principal investigator in multiple international clinical trials mainly related to heart failure.
He is a Board Member and Fellow of the Heart Failure Association (HFA) of the European Society of Cardiology and holds the following positions:
- Coordinator the Exercise Physiology and Training Committee of the HFA
- Coordinator of Endorsement Committee for Higher Educatio of the HFA
- Co-coordinator of the Registry and Epidemiology Committee of the HFA
- HFA Liaison officer of the ESC Digital Committee
- Member of the HFA Study Group on Cachexia, Sarcopenia and Frailty
